Tag: Triple-Gene

Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN‑4001, First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure

Coronary/Structural Heart by 0 comments

– Company to Present Preliminary Data at American Heart Association Scientific Sessions – GERMANTOWN, Md., Nov. 7, 2019 /PRNewswire/ — Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), today announced the completion of enrollment […]

Continue Reading →